Lightnews — Scholar-powered news

Reposted by Prof Nancy Devlin

EuroQol Research Foundation @euroqol.bsky.social · Aug 19

EQ-TIPS was developed to meet growing interest in evaluating the effectiveness & cost-effectiveness of treatments in very young children 👶

In this paper, @prof-nancy-devlin.bsky.social et al. examine issues in valuing the EQ-TIPS and possible adaptations to valuation methods 👉 bit.ly/4oxl4gF

Text: ‘Publication, Paper Tuesday - Valuing health states for infants and toddlers: challenges and methodological considerations in EQ-TIPS preferences elicitation. by Devlin, N. et al. (2025).' The background is a gradient blue with overlaid images of books and the world map.

2 3

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jul 28

in a good way, though, I hope! :-)

1 1

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jul 27

New paper: "Measuring & Valuing Health Using EuroQol Instruments: New Developments 2025 and Beyond"

▶️open access: tinyurl.com/EuroQol2025u...

@fengtastic.bsky.social @beaunebeaune.bsky.social @ellystolk.bsky.social

#HealthEconomics #PROMS #HRQOL #EQ-5D #EQ-5D-Y #EQ-HWB-9 #EQ-TIPS #Bolt-ons

Highlight points from a new paper summarising established and new tools for measuring and valuing health related quality of life, developed by a not for profit organisation called the EuroQol Research Foundation.

5

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jul 23

Thanks @frasermorton.bsky.social for adding the Australian value set for the EQ-5D-Y-3L to your #rstats #EQ5D package! That was quick work!

@euroqol.bsky.social @rich-norman.bsky.social
Our paper is available here, open access:
➡️https://tinyurl.com/AussieY-3Lvalueset

4

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jul 12

I'm looking forward to the 2025 #iHEA Congress, & the pre-congress @euroqol.bsky.social session.

Authors: If you're presenting a paper at iHEA & thinking of submitting it to #ValueinHealth - drop me a message! I'll do my best to come to your session. Or just come up & say hi!

#healtheconomics #VIH

1 4

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jul 11

Will Trump's plan to use 'Reference Pricing' cut US drug prices? This #ValueinHealth paper by Grueger, Martin & Sullivan argues reference pricing is ill-advised & will lead to unintended consequences.

open access 👉 tinyurl.com/reference-pr...

#Trump #HealthEconomics

Image is copyright to Jane Doe/ Shutterstock. Shows a cartoon image of Donald Trump with a signed Executive Order

1 2 2

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jun 22

News from the English NHS: www.bbc.com/news/article...

#genomics #precisionmedicine
@eigen-uom.bsky.social

NHS plans to DNA test all babies in England to assess disease risk

Scheme is part of the government's 10-year plan for the NHS in England aimed at easing pressure on services.

www.bbc.com

1

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jun 22

New impact factor for Value in Health. We're chuffed!
#healtheconomics

1 11

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jun 22

This letter, in the June issue of Value in Health, makes for pretty interesting reading:
www.valueinhealthjournal.com/article/S109...

#healtheconomics #equity #HTA

Why Is Distributional Cost-Effectiveness Analysis Not Ready for Prime Time in Health Technology Assessment?

The systematic review by Merga et al1 examining economic evaluations that address inequalities in cancer care had a striking result in that only 13% of studies identified used distributional cost-effe...

www.valueinhealthjournal.com

1

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jun 22

New Value in Health paper, "Drop the M", of interest to anyone struggling with how to interpret data from patient reported outcome measures, and what a Minimally Important Difference means. Authors: Vickers, Nolla & Cella.
👉 pubmed.ncbi.nlm.nih.gov/40216310/

#HealthEconomics

Drop the "M": Minimally Important Difference and Change Are Not Independent Properties of an Instrument and Cannot Be Determined as a Single Value Using Statistical Methods - PubMed

MID must be estimated within a specific study context. It is best to think of PRO measures in terms of "ID" and leave the "M" to case-by-case, context-based interpretation.

pubmed.ncbi.nlm.nih.gov

1

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jun 18

Thank you!! 👍

2

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jun 15

Hey @altmetric.com, I was wondering if you've got any updates on this you could share? #AcadmicSky #EconSky

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Apr 25

How are X and @bsky.app performing as platforms for disseminating research? Fascinating @altmetric.com analysis here:
www.altmetric.com/blog/bluesky...
#AcademicSky #EconSky

Bluesky’s ahead, but is X a dead parrot?

Altmetric has been capturing and integrating Bluesky posts since October 2024. What does the data look like now?

www.altmetric.com

1 2 16

Reposted by Prof Nancy Devlin

David Edmonds @davidedmonds100.bsky.social · May 6

Two great philosophers retiring. Two conferences to honour them. Two great line ups. Both open to the public. Sign up.
Jo Wolff www.bsg.ox.ac.uk/events/publi...
& Jeff McMahan
www.ccc.ox.ac.uk/alumni/event...

The Public Philosopher

Join us for a day of philosophical discussion in honour of Professor Jo Wolff's career.

www.bsg.ox.ac.uk

2 6

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 17

Nice work @lauratrigg.bsky.social! 🙌 We need to see much more of this kind of evidence on the cost effectiveness of existing healthcare interventions. b.t.w,@jappleby123.bsky.social @koonalshah.bsky.social looked at hip surgery in 2013, using NHS PROMS data: pubmed.ncbi.nlm.nih.gov/23759892/

Using patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitals - PubMed

Using the new patient-assessed health-related quality of life data combined with routine hospital-level cost data it is possible to estimate a procedure-based measure of efficiency for hospitals. The ...

pubmed.ncbi.nlm.nih.gov

1 1 1

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 16

Tomorrow at #ISPOR2025: in this 75-min 'spotlight' session we will give in-depth consideration of whether Cost Benefit Analysis could play a bigger role in HTA. If you are here in Montreal, I hope to see you there!
#HealthEconomics

A powerpoint slide from Prof. Devlin linking the case for CBA to the need for cross-sectoral economic evaluation

3

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 16

An update on NICE methods regarding health inequalities in health technology evaluations is out now:

tinyurl.com/NICEmethodsh...

#HealthEconomics

Health inequalities - an update to NICE’s methods for health technology evaluation

www.nice.org.uk

3

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 14

@euroqol.bsky.social puts out these useful posts regularly, where they do a quick ‘round-up ’ of new papers published about EQ-5D and related instruments. I find therir posts very helpful. If you’re interested in HRQoL, utilities etc, it’s worth following them!
#HealthEconomics #PROMs

EuroQol Research Foundation @euroqol.bsky.social · May 14

Brand new selection of scientific papers on EuroQol instruments listed below - check them all out! 📚

1/

1 3

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 14

#ISPORAnnual Virginia Acha notes that tough pricing regulation in the US will reduce incentives for investment in innovation - and this is a double whammy if coupled with reduced US funding of basic science.
#referencepricing #HealthEconomics

5

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 14

At ISPOR 2025 Darius Lakdawalla: some form of price intervention is now inevitable in the US, hopefully based on value, and done in a ‘US specific way’. Time for the US to adopt its own HTA.

1 1

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 14

At today’s ISPOR conference: Sean Sullivan arguing US reference pricing is ‘lazy and misguided’ - but has bipartisan support.

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 13

I'm guessing this is going to be a hot topic of conversation here at ISPOR Montreal over the coming days!
www.theguardian.com/business/202...
#HealthEconomics

Drug price cuts: what is Trump planning and what will it mean for big pharma?

President has directed Robert Kennedy to send price targets to industry, with slimming drugs thought to be included

www.theguardian.com

2

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 12

Will the US introduce 'reference pricing'?
www.reuters.com/business/hea...

Trump to sign executive order on reducing prescription drug prices

U.S. President Donald Trump said on Sunday he would sign an executive order that he said would reduce prescription drug and pharmaceutical prices by between 30% and 80%.

www.reuters.com

1

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 12

[2/2] So, after the 10-year exclusivity period ends, what happens? Not much: despite expectations of price reductions, the authors observe that many orphan meds seem to lack competition.
@amsterdamumc.bsky.social

This 'Editor's Choice' paper is available open access: tinyurl.com/EUOrphanMeds

3

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 12

[1/2] "24 yrs After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars & Generics for Orphan Medicinal Products"by Sibren van den Berg & colleagues in the May issue of Value in Health @amsterdamumc.bsky.social

👉 tinyurl.com/EUOrphanMeds
#HealthEconomics

abstract of a new paper just published in Value in Health, May 2025, Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products

1 2

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 12

"The Price Effects of Biosimilars In the US" by Mireia Jofre-Bonet et al. concludes the US biosimilars market has become highly competitive; driving price reductions between 2015-2023 with substantial savings for Medicare

➡️ tinyurl.com/PriceEffects...

@ohenews.bsky.social
#HealthEconomics

abstract of a new paper in Value in Health, May 2025, by Mireia Jofre-Bonet and colleagues about the effect of biosimilars on prices in the US

1 2